Sixteen months experience with cyclosporin-A in human kidney transplantation.
CY-A is a potent immunosuppressive agent and can prevent graft rejection. In our experience hirsutism and viral infections are marked. Lymphomas may be more common in CY-A-treated patients than in those treated conventionally. Smaller doses of CY-A given for shorter periods before conversion to conventional treatment may be a better way to use this new agent.
D002986:Clinical Trials as Topic; D003524:Cyclosporins; D004305:Dose-Response Relationship, Drug; D006084:Graft Rejection / Q000187:drug effects*; D006628:Hirsutism / Q000453:epidemiology; D006801:Humans; D016030:Kidney Transplantation; D008223:Lymphoma / Q000453:epidemiology; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D014777:Virus Diseases / Q000453:epidemiology
D003524:Cyclosporins; D010456:Peptides, Cyclic; D011241:Prednisone